title: Targeting the adenosine A2b receptor in the tumor microenvironment overcomes local immunosuppression by myeloid-derived suppressor cells.
abstract: Emerging evidence suggests that the adenosine A2b receptor (ADORA2B, also known as A2bR) plays a pivotal role in tumor progression. We have recently demonstrated that blocking A2bR stimulates T cell-mediated immunosurveillance in a melanoma model by impairing the influx of myeloid-deriver suppressor cells (MDSCs) into the tumor microenvironment. This results in robust antineoplastic effects, which can be abrogated by the adoptive transfer of MDSCs.
authors.affiliation: Department of Pharmacy; University of Salerno; Salerno, Italy.
authors.forename: Silvana
authors.initials: S
authors.lastname: Morello
authors.affiliation: Cancer Institute and Departments of Medicine and Pharmacology; University of Mississippi Medical Center; Jackson, MS USA.
authors.forename: Lucio
authors.initials: L
authors.lastname: Miele
keywords: A2bR; MDSCs; immunosuppression; immunotherapy; tumor microenvironment
references.citation: Neoplasia. 2008 Sep;10(9):987-95
references.pmid: 18714400
references.citation: Neoplasia. 2013 Dec;15(12):1400-9
references.pmid: 24403862
references.citation: Nat Rev Immunol. 2009 Mar;9(3):162-74
references.pmid: 19197294
references.citation: Cancer Res. 2011 Dec 15;71(24):7463-70
references.pmid: 22025564
references.citation: J Immunol. 2011 Dec 1;187(11):6120-9
references.pmid: 22039302
references.citation: Int J Cancer. 2006 Nov 1;119(9):2044-53
references.pmid: 16823836
references.citation: Nat Rev Cancer. 2008 Aug;8(8):618-31
references.pmid: 18633355
references.citation: J Clin Invest. 2008 Oct;118(10):3367-77
references.pmid: 18776941
references.citation: Nat Rev Immunol. 2012 Mar 22;12(4):253-68
references.pmid: 22437938